Noven Drug Patent Portfolio
Noven owns 1 orange book drug protected by 8 US patents Given below is the list of Noven's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8231906 | Transdermal estrogen device and delivery | 04 Jul, 2030 | Active |
| US9724310 | Transdermal estrogen device and delivery | 10 Jul, 2028 | Active |
| US9730900 | Transdermal estrogen device and delivery | 10 Jul, 2028 | Active |
| US9833419 | Transdermal estrogen device and delivery | 10 Jul, 2028 | Active |
| US6841716 | Patch | 27 Apr, 2020 | Expired |
| US5646286 | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines | 12 Aug, 2014 | Expired |
| US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 12 Aug, 2014 | Expired |
| US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 07 Jan, 2014 | Expired |
Latest Legal Activities on Noven's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Noven.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jan, 2024 | US8231906 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2021 | US9833419 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2021 | US9730900 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2021 | US9724310 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Dec, 2019 | US8231906 |
| Termination or Final Written Decision | 10 Sep, 2018 | US9833419 |
|
Request for Trial Denied
Critical
| 12 Jun, 2018 | US9730900 |
|
Request for Trial Denied
Critical
| 12 Jun, 2018 | US9724310 |
| Petition Requesting Trial | 18 May, 2018 | US9833419 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Dec, 2017 | US9833419 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Dec, 2017 | US9833419 |
| Petition Requesting Trial | 04 Dec, 2017 | US9730900 |
| Petition Requesting Trial | 04 Dec, 2017 | US9724310 |
|
Email Notification
Critical
| 17 Nov, 2017 | US9833419 |
|
Issue Notification Mailed
Critical
| 15 Nov, 2017 | US9833419 |
Noven's Drug Patent Litigations
Noven's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 04, 2017, against patent number US9730900. The petitioner Mylan Technologies, Inc., challenged the validity of this patent, with Noven Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Noven's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9833419 | May, 2018 |
Terminated-Settled
(10 Sep, 2018)
| Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| US9724310 | December, 2017 |
Terminated-Settled
(12 Jun, 2018)
| Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| US9730900 | December, 2017 |
Terminated-Settled
(12 Jun, 2018)
| Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
Noven Drug Patents' Oppositions Filed in EPO
Noven drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 23, 2016, by 3M Innovative Properties Company. This opposition was filed on patent number EP09790211A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP09790211A | Mar, 2016 | 3M Innovative Properties Company | Revoked |
Noven's Family Patents
Noven Drug List
Given below is the complete list of Noven's drugs and the patents protecting them.
1. Minivelle
Minivelle is protected by 8 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8231906 | Transdermal estrogen device and delivery |
04 Jul, 2030
(4 years from now)
| Active |
| US9724310 | Transdermal estrogen device and delivery |
10 Jul, 2028
(3 years from now)
| Active |
| US9730900 | Transdermal estrogen device and delivery |
10 Jul, 2028
(3 years from now)
| Active |
| US9833419 | Transdermal estrogen device and delivery |
10 Jul, 2028
(3 years from now)
| Active |
| US6841716 | Patch |
27 Apr, 2020
(5 years ago)
| Expired |
| US5646286 | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines |
12 Aug, 2014
(10 years ago)
| Expired |
| US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
12 Aug, 2014
(10 years ago)
| Expired |
| US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
07 Jan, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Minivelle's drug page